News

Le Lézard17h
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
AbbVie  today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe ...
Breaking Down All the Types of Botox: Botox, Xeomin, Dysport, Jeuveau, and Daxxify
When I say I’ve been getting Botox my entire adult life, I’m not exaggerating one bit—I started at the ripe, young age of 19 ...
Pharmabiz14d
argenx SE highlights VYVGART data setting new standard in efficacy and improved quality of life measures for patients with gMG and CIDP
Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...
Seeking Alpha16d
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Treatment-emergent adverse events (TEAEs) were consistent with label and no new events ... to promote maturation and stabilization of the neuromuscular junction (NMJ). MuSK is a receptor kinase ...
Morningstar16d
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
The study consisted of a 24-week double-blind treatment stage and an open-label treatment stage ... MG is an autoimmune disease caused by neuromuscular junction transmission disorders.
PR Newswire17d
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
The study consisted of a 24-week double-blind treatment stage and an open-label treatment stage ... MG is an autoimmune disease caused by neuromuscular junction transmission disorders. It is ...
Benzinga.com14d
Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US
Stimel-03 integrates FES, NMES, and real-time EMG biofeedback in one platform. FDA-cleared Stimel-03 supports stroke, injury, and surgery rehab in clinics and homes. Feel unsure about the market ...
MedPage Today15d
Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab
SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...